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Diarrheagenic Escherichia coli (DEC) are important agents of endemic and epidemic16
diarrhea worldwide, as well as significant contributors of travelers’ diarrhea in industrialized17
countries (1, 2). The most important DEC pathotypes are Shiga toxin-producing E. coli18
(STEC), enteropathogenic E. coli (EPEC), further divided into typical (tEPEC) and atypical19
(aEPEC), enterotoxigenic E. coli (ETEC), enteroinvasive E. coli (EIEC), and20
enteroaggregative E. coli (EAEC) (2). STEC are foodborne pathogens responsible for21
important outbreaks of hemorrhagic colitis (HC) and hemolytic-uremic syndrome (HUS) in22
industrialized countries (2). EAEC, ETEC, EPEC, and EIEC are generally considered major23
causes of travelers’ diarrhea in adults from developed countries and the leading causes of24
infant diarrhea in developing ones (2).25
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The first-choice agents for treating DEC infections are quinolones, together with26
rifaximin and azithromycin (3), although the use of quinolones concretely in STEC27
complicated infections remains controversial, as they have been postulated to increase the28
risk of development of HUS (4). However, plasmid-mediated quinolone resistance genes29
(qnr) encoding small pentapeptide-repeat proteins that protect type II DNA topoisomerases30
from quinolones have been described, including five qnr families [qnrA1–7, qnrB1–74, qnrC,31
qnrD1-2 and qnrS1–9 (http://www.lahey.org/qnrstudies)]. qnr genes by themselves are able32
to confer only a low-level quinolone resistance, but they have been proposed to promote the33
emergence of chromosomal mutations leading to resistance levels of clinical significance (5).34
Although the occurrence of qnr genes has been widely documented in extraintestinal E. coli35
(6), studies concerning qnr occurrence in DEC are scarce and, as far as we know, it has not36
been reported yet in clinical DEC strains other than EAEC (7, 8).37
A routine screening for susceptibility to 13 different antimicrobials was carried out with38
54 STEC, 16 aEPEC, 9 EAEC, 6 ETEC, and 2 EIEC strains (87 strains in total) isolated from39
complicated (HC and HUS) and non-complicated endemic diarrhea and travelers’ diarrhea40
cases in the Spanish National Reference Laboratory (SNRL) during 2012 and 2013. The41
susceptibility testing was performed by the disk diffusion method and results were interpreted42
according to CLSI guidelines. The panel included ampicillin, cefalotin, cefotaxime,43
amoxicillin/clavulanic acid, tetracycline, streptomycin, kanamycin, gentamicin, nalidixic44
acid, ciprofloxacin, chloramphenicol, trimethoprim/sulfamethoxazole, and a sulphonamide45
compound. For strains showing a decrease in the diameter of the inhibition halo of46
ciprofloxacin (≤27 mm) the MICs of ciprofloxacin and nalidixic acid were determined by 47
Etests. Additionally, to evaluate the possible association between qnr genes and the48
production of ESBLs, the ESBL phenotype was detected by the double synergy test. PCR and49
DNA sequencing were used to confirm the presence of qnr genes and identify the qnrA,50
3
qnrB, qnrC, qnrD, and qnrS alleles, as well as β-lactamase (bla) alleles, as previously51
described (9). Conjugation experiments were used to determine the transfer of resistance52
using a rifampicin-resistant E. coli as recipient and all qnr-harbouring strains as donors and53
rifampicin (50 μg/ml) and ampicillin/streptomycin (100 μg/ml) to select transconjugants (9). 54
The presence of plasmids and plasmid sizes were assessed by S1-PFGE and plasmid55
extraction with the QIAprep Spin Miniprep Kit (Qiagen) from every parental and56
transconjugant strain, and their incompatibility groups were established by PCR-based57
replicon typing (10). The location of qnr and bla genes was determined by Southern blot58
hybridization using PCR-generated digoxigenin-labelled probes (9).59
Overall, four DEC strains out of 87 (4.6%) exhibited a decreased ciprofloxacin60
susceptibility (MIC 0.38-1.5 μg/ml), with three of them being still susceptible to nalidixic 61
acid (MIC 6-16 μg/ml) (Table 1). As these values have been previously proposed to identify 62
qnr-positive strains (5, 9), the presence of qnr genes was confirmed on the four strains.63
Concretely, qnrB19 was identified in an EAEC strain isolated from an adult with diarrhea64
travelling from Mexico and also in a STEC O157:H7 strain isolated from a 7-year-old boy65
suffering from HUS after diarrhea (Table 1). Likewise, qnrS1 was detected in an aEPEC66
strain isolated from a 1-year-old boy with non-complicated diarrhea and also in an EIEC67
strain isolated from an adult with diarrhea travelling from South-East Asia (Table 1). This68
latter EIEC strain showed a resistance phenotype indicating ESBL production and harbored69
the ESBL gene blaCTX-M-15 (Table 1). Conjugation experiments were positive for the EAEC,70
aEPEC, and EIEC strains, and therefore three transconjugants were obtained. Plasmid71
analysis showed that qnrB19 was transferred on a ColETp plasmid of ≈3 kb in the EAEC 72
strain (Table 1). In the aEPEC strain, qnrS1 was transferred on a non-typeable plasmid of ≈48 73
kb, and co-transfer of blaTEM1 gene was observed (Table 1). In the ESBL-producing EIEC74
strain, qnrS1 was transferred with blaCTX-M-15 and blaTEM1 on an IncK plasmid of ≈97 kb 75
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(Table 1). Finally, in the STEC O157:H7 strain, qnrB19 was harboured on a non-conjugative76
ColETp plasmid of ≈3.5 kb (Table 1).  77
To our knowledge this is the first report of the occurrence of qnr genes in STEC, aEPEC,78
and EIEC clinical strains. Our study also confirms the occurrence of qnr genes in EAEC79
strains reported by Riveros et al. (7) and Kim et al. (8), which might have contributed to the80
increasing trend of fluoroquinolone resistance recently observed in this E. coli pathotype81
worldwide (7, 11). As for the plasmids, although qnrB19 has previously been found in ColE-82
like plasmids (7, 12), qnrS1 has rarely been found in incK plasmids, mainly involved in the83
spreading of blaCTX-M-14 (13). Many surveys have shown qnr-positive Enterobacteriaceae84
simultaneously expressing plasmid-encoded β-lactamases, because genes encoding ESBLs 85
and AmpC β-lactamases are often found on the same plasmid than qnr genes (5, 9).86
Nevertheless, although the presence of blaCTX-M-15 in incK plasmids from E. coli has been87
recently reported (14) and qnrS1 has been recently found linked to the AmpC β-lactamase 88
blaCMY-2 in multiresistance incK plasmids from E. coli (15), to our knowledge no IncK89
plasmid simultaneously harboring qnrS1 and blaCTX-M-15 has been reported yet.90
Although the clinical implications of our findings are still unknown, it may be speculated91
that qnr genes might play a significant role in therapeutic failures in DEC infections and so92
this is very important to take into consideration when working with diarrhea cases and their93
treatment. In addition, epidemiologic surveillance and correct use of antimicrobial agents are94
needed to limit the spread of plasmid-mediated quinolone resistances.95
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TABLE 1 Features of the four qnr-positive diarrheagenic Escherichia coli strains157









2384/12 EAEC TD O65/O71:H1a qnrB19 AMP, CHL, TET, AMC
SXT, AMC, blaTEM1, blaCTX-M-15
12/0.38 3/ColETp
4425/12 STEC CD O157:H7 qnrB19 AMP, SSS, STR, TET, SXT 16/0.38 3.5/ColETp
4472/12 aEPEC NCD O49:H- qnrS1 AMP, SSS, NAL, TET
blaTEM1
>256/1.5 48/NT
2113/13 EIEC TD O96:H19 qnrS1 AMP, SSS, STR, CEF, CTX, SXT, AMC
blaTEM1, blaCTX-M-15
6/0.38 97/IncK
NAL, nalidixic acid; CIP, ciprofloxacin; EAEC, enteroaggregative E. coli; STEC, Shiga toxin-producing E. coli; aEPEC, atypical enteropathogenic E. coli; EIEC,
enteroinvasive E. coli; TD, travelers’ diarrhea; CD, complicated endemic diarrhea; NCD, non-complicated endemic diarrhea; H−, non-motile; AMP, ampicillin; CHL, 
chloramphenicol; TET, tetracycline; AMC, amoxicillin/clavulanic acid; SSS, sulphonamides; STR, streptomycin; SXT, trimethoprim/sulfamethoxazole; CEF, cefalotin;
CTX, cefotaxime; NT, non-typeable.
a The strain cross-reacted with the respective O antisera.
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